Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 12/20 | 0.60 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915682 | 1.00 | GALR3 (0.60) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL6905755 | 0.91 | GALR3 (0.58) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL8171379 | 0.91 | GALR3 (0.58) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL8360397 | 0.90 | GALR3 (0.50) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL916817 | 0.89 | GALR3 (0.68) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL916818 | 0.89 | GALR3 (0.68) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL918040 | 0.87 | GALR3 (0.58) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL918039 | 0.87 | GALR3 (0.58) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL8089758 | 0.85 | GALR3 (0.46) | GALR3HTR4MAPTKMT2AMEN1 | |
| SCHEMBL916940 | 0.83 | GALR3 (0.64) | GALR3HTR4MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198313-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2011-07-21 | — | — | US | disclosed |
| US-7868034-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| US-7868034-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| EP-2241316-A1 | Indolone compounds useful to treat cognitive impairment | Helicon Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2241316-A1 | Indolone compounds useful to treat cognitive impairment | Helicon Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1957067-B1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | HELICON THERAPEUTICS INC (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100179187-A1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-07-15 | — | — | US | disclosed |
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20070054910-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | KONKEL MICHAEL | 2007-03-08 | — | — | US | disclosed |
| US-20070054910-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | KONKEL MICHAEL | 2007-03-08 | — | — | US | disclosed |
| US-20070054910-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | KONKEL MICHAEL | 2007-03-08 | — | — | US | disclosed |
| US-7081470-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S | 2006-07-25 | — | — | US | disclosed |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040102507-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2004-05-27 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| WO-2004014307-A2 | GAL3 ANTAGONISTS FOR THE TREATMENT OF NEUROPATHIC PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179187-A1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | CHAT, AANAT, TPH2 | GALR3 450/4885HTR4 12/4885MAPT 100/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 30/4885MAPT 3040/4885 |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 30/4885MAPT 2912/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 17/4885MAPT 1723/4885 |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 24/4885MAPT 3133/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 214/4885MAPT 3177/4885 |
| US-20070054910-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 30/4885MAPT 2912/4885 |
| US-20040102507-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 30/4885MAPT 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.